中 . EN
Copyright © Indetek Laboratory
苏ICP备2023008818号

Technology Platform

Indetek’s proprietary ILDS® transdermal delivery system is a new patented drug delivery platform. It has the following features.
  • Unmet clinical needs

    The three key unmet needs in dermatology disease
    management are “limited treatment options",
    "ineffectiveness of available therapies" and "poor adherence to treatment".

  • Possible solutions

    Development of NCE and new formulations with better efficacy
    Improves transdermal efficiency to increase efficacy, simplifies treatments and reduces adverse effects
    Better aesthetic acceptability and physical sensation of use

ILDS@
transdermal delivery system
  • 01
    Customizing

    Innovative technology platform that can be customized to form a series of products based on specific APl and disease

  • 02
    Improved efficacy

    Significantly improve the efficiency of transdermal, while leveraging long-lasting effect, and reduce the number of doses

  • 03
    Good compliance

    No need to use dressing, easy to use, transparent and beautiful appearance, improve patient compliance

  • 04
    Good tolerance

    Good clinical data demonstrating excellent skin tolerability

  • 05
    Additional skin protection

    Creates a breathable barrier to protect lesions while promoting skin healing

Cases Study

  • ILDS® improves transdermal absorption of insoluble small molecules

    • Test drug:

      IDT-003 (almost insoluble in water, solubility about 0.00477g/L)

    • Equipment:

      Transdermal diffusion tester, model TK-24BL

    • Skin material:

      Isolated skin from Parmesan minipigs’ back

    • Receiving fluid:

      saline, 32±0.5°C, 400 rpm agitation

    • Test group:

      in-house developed ILDS® formulation (three different prescriptions)

    • Control group:

      U.S. reference drug (US RLD)

    • Dosage:

      300mg±10 mg

    • Sampling time:

      6h

    • Test sample:

      Determination of drug content retained in skin samples after exfoliation

    Conclusion：Compared to US RLD, ILDS® promotes the transdermal absorption of insoluble small molecule IDT-003 and increases intracutaneous retention up to 4-5 times

  • ILDS® improves transdermal absorption of water-soluble small molecules

    • Test drug:

      Pro-xylane

    • Equipment:

      Transdermal diffusion tester, model TK-24BL

    • Skin material:

      Isolated skin from Parmesan minipigs’ back

    • Receiving fluid:

      saline, 32±0.5°C, 400 rpm agitation

    • Test group:

      in-house developed ILDS® formulation

    • Control group:

      U.S. reference drug (US RLD)

    • Dosage:

      300mg±10 mg

    • Sampling time:

      6h

    • Test sample:

      Determination of drug content retained in skin samples after exfoliation

    Conclusion：Compared to branded product 修*可 , ILDS® promotes the transdermal absorption of soluble small molecule Pro-xylane and increases intracutaneous retention up to about 12 times

  • ILDS® improves transdermal absorption of water-soluble macromolecules

    • Test drug:

      Hyaluronic acid labeled by rhodamine-B (RhB), molecular weight 200,000-300,000 Da

    • Equipment:

      Transdermal diffusion tester, model TK-24BL

    • Skin material:

      Isolated skin from Parmesan minipigs’ back

    • Receiving fluid:

      saline, 32±0.5°C, 400 rpm agitation

    • Test group:

      in-house developed ILDS® -RhB-HA （0.1%）formulation

    • Control group:

      RhB-HA （0.1%）

    • Dosage:

      300mg±10 mg

    • Sampling time:

      6h

    • Test sample:

      Skin samples were exfoliated and frozen sectioned, and the exogenous HA transdermal condition was determined qualitatively by measuring red fluorescence through fluorescence microscopy

    Results and Conculsion:
    • In the RhB-HA group, red fluorescence was observed only in the residual stratum corneum, indicating that the RhB-HA solution was unable to penetrate the stratum corneum barrier
    • In the ILDS® -RhB-HA group, in addition to the red fluorescence observed in the residual stratum corneum, continuous and uniform fluorescence penetration was also observed in both the epidermis and dermis, indicating that ILDS® can significantly improve transdermal absorption of water-soluble macromolecule HA